


[Welcome](#)
[Program](#)
[Registration](#)
[Hotel & Venue](#)
[Travel](#)
[Sponsors & Exhibitors](#)

IPCC2017 | PROGRAM-AT-A-GLANCE | DAY 3

SAT AUG 26

SUN AUG 27 | DAY 1

MON AUG 28 | DAY 2

TUES AUG 29 | DAY 3

WED AUG 30 | DAY 4

 DOWNLOAD
DIGITAL
PROGRAM

TUESDAY AUGUST 29 | DAY 3
Program subject to change - check the app for the most current updates.

TIME	MEETING ROOM	SESSION
6:45am - 8:00am		<p>Women In Science Breakfast</p> <p>Barbara A. Gilchrest, M.D., received her undergraduate and medical training from the Massachusetts Institute of Technology (MIT) and Harvard Medical School (HMS) respectively. After a post-doctoral fellowship in the laboratory of Howard Green at MIT, in 1977 Dr. Gilchrest joined the Department of Dermatology and Division on Aging at the HMS, where she established a tissue culture laboratory to study the aging process in human skin, with support from the National Institute on Aging (NIA).</p> <p>From 1985 until 2008, Dr. Gilchrest served as Professor and Chairman of Dermatology at the Boston University School of Medicine, where she directed a large laboratory and an NIH-sponsored post- doctoral research-training program. Her laboratory studied cellular aging, regulation of melanogenesis, and telomere-based protective responses in the skin; complementary clinical research interests focused on therapeutic uses of light in dermatology. She remained as Professor on a part-time basis until 2014 while serving as Editor-in-Chief for the Journal of Investigative Dermatology (2012-17).</p> <p>In 2015, she joined the Department of Dermatology at the Massachusetts General Hospital and HMS as Professor- in-Residence. Dr. Gilchrest is the author of over 400 scholarly articles, reviews, abstracts, and textbook chapters; and author or editor of eight books. She has served in leadership positions for all the major dermatologic organizations; on the National Advisory Council on Aging and the Board of Scientific Counselors of the National Cancer Institute. She serves as associate editor or editorial board member of several major clinical and research journals; as a consultant or scientific advisory board member for pharmaceutical and biotechnology companies; and as a member of the MIT Corporation (1995-2005).</p> <p>Dr. Gilchrest is a Fellow of the American Association for the Advancement of Science, an elected member of the Institute of Medicine of the National Academies of Science, and a Charter member of the National Academy of Inventors.</p>
8:00am - 3:30pm	South Convention Lobby	Registration Open
8:00am - 10:00am	Grand Ballroom II	<p>PS06. Melanoma: Breakthroughs in Melanoma Research <i>Outstanding melanoma researchers will present their breakthrough research, providing new avenues of investigation for the field.</i></p> <p>Session Chair: Andrew Aplin, Martin McMahon</p>

		<ul style="list-style-type: none"> Precision medicine for melanoma: are we there yet? [30 mins] <i>Keynote Speaker: Richard Marais</i> Overcoming early adaptation to inhibition of BRAF in melanoma [30 mins] <i>Speaker: Grant McArthur</i> Imaging and targeting pre-metastatic niches in melanoma [30 mins] <i>Speaker: Maria Soengas</i> Strategies to target phenotypic plasticity in melanoma [30 mins] <i>Speaker: Kieran Smalley</i>
10:30am - 3:30pm	Grand Ballroom I	Exhibit Hall Open
10:00am - 10:30am	Grand Ballroom I	REFRESHMENT BREAK
10:30am - 12:00pm	Grand Ballroom II	<p>Concurrent Sessions 17-20</p> <p>CS17. Genetics and Epigenetic Control of Melanoma <i>This session will address genetic and epigenetic control of melanoma, with particular emphasis on genomic approaches to the study of melanoma.</i></p> <p>Session Chair: Marcus Bosenberg, Hensin Tsao</p> <ul style="list-style-type: none"> Rare variant, gene-based association study of hereditary melanoma [20 mins] <i>Speaker: Hensin Tsao</i> Differences in mutational processes and driver genes between acral, mucosal and cutaneous melanomas [20 mins] <i>Speaker: Nicholas Hayward</i> Melanin pigment and melanoma heterogeneity [20 mins] <i>Speaker: Mark Shackleton</i> Genome-wide DNA methylation analysis in melanocytes and melanomas from the same individual [10 mins] <i>Susumu Fujiwara</i> Whole Exome Sequencing Identifies Recurrent R625 Mutations in Novel Drug Target and Driver, SF3B1 in the Largest Cohort to Date of Mucosal Melanoma [10 mins] <i>Jennifer Hintzsche</i> Precision targeting of epigenomic master regulators in malignant melanoma [10 mins] <i>Fabian Filipp</i>
	Tower Court C	<p>CS18. Lasers and Light Devices <i>This session will address the history of the field, as well as the latest advances in the use of light and lasers to treat pigmentary disorders.</i></p> <p>Session Chair: Adrian Mar, Thierry Passeron, Iltefat Hamzavi</p> <ul style="list-style-type: none"> Melanocytes sense blue-light and regulate the pigmentation through the Opsin 3 [20 mins] <i>Speaker: Thierry Passeron</i> Understanding How Lights and Lasers Can Tune Pigment Up or Down [20 mins] <i>Speaker: Iltefat Hamzavi</i> Comparison of 311-nm Ti:Sapphire laser vs. 308-nm Excimer Laser treatment for vitiligo: A prospective randomized controlled non-inferiority trial [15 mins] <i>Jung-Min Bae</i> Fluticasone propionate 0.05% cream improves repigmentation in narrow-band UVB phototherapy of non-segmental vitiligo: a randomized controlled trial [15 mins] <i>Albert Wolkenstorfer</i> Laser treatment of congenital melanocytic nevi: a systematic review [10 mins] <i>Janny Lommerts</i> The Synergistic Effect of Minimal Amounts of Long-Wavelength Ultraviolet A1 and Visible Light on Pigmentation [10 mins] <i>Indermeet Kohli</i>
	Tower Court D	<p>CS19. Non-Mouse Animal Models of Pigmentation <i>This session will address recent advances using non-mouse animal models of pigmentation and disorders.</i></p> <p>Session Chair: Gisela Erf, Toyoko Akiyama, Robert Cornell, Elizabeth Patton</p>

		<ul style="list-style-type: none"> Targeting the Developmental Melanocyte Lineage in Melanoma [20 mins] <i>Speaker: Elizabeth Patton</i> GDF6-induced BMP signaling reawakens a neural crest identity in melanoma to prevent differentiation and cell death [20 mins] <i>Speaker: Craig Ceol</i> Avian Pigment Pattern Formation [20 mins] <i>Cheng-Ming Chuong</i> Genetic basis of normal and transformed pigment cells in the Xiphophorus and medaka model [20 mins] <i>Manfred Schartl</i> A zebrafish model of NF1-mutant melanomas that lack activating mutations of BRAF or NRAS [10 mins] <i>Shuning He</i>
--	--	--

	Windows	<p>CS20. Melanoma: Emerging Therapies I <i>This session will address ways to enhance present immune therapies, treatments using genetically modified T cells, treatments that activate various immune effectors, new vaccines for melanoma, and predictive biomarkers.</i></p> <p>Session Chairs: Maria Wei, Martin McCarter, Brian Gabrielli</p> <ul style="list-style-type: none"> Increasing replication stress by reducing nucleoside levels sensitises melanoma to CHK1 inhibitors in vitro and in vivo [20 mins] <i>Speaker: Brian Gabrielli</i> Overall survival with nivolumab (NIVO) and ipilimumab (IPI) combination therapy in a phase III trial of advanced melanoma (CheckMate 067) [20 mins] <i>Speaker: Theresa Medina</i> Immunotherapy plus mapk targeted therapy [20 mins] <i>Speaker: Ryan Sullivan</i> Targeting Glutamatergic Signaling and PD-1 Checkpoint Inhibition to Treat Melanoma in an Experimental System [20 mins] <i>Speaker: Yosef Refaeli</i> T cell receptors help define the cytokine pattern and responsiveness of host CD8 T cells [10 mins] <i>Chris Ankney</i>
--	---------	--

12:15pm - 1:15pm

Grand Ballroom II

SY04. Lunch Symposium: Biomarkers In Melanoma. Why Does Prognosis Matter?

- Speaker: Jason J. Luke, MD, FACP
- Speaker: John Vetto, MD

This session is supported in part by an educational grant from:




1:30pm - 3:00pm	Windows	<p>Concurrent Sessions 21-24</p> <p>CS21. Hair Biology and Pigmentation <i>This session will address the importance of the hair follicle in skin and hair pigmentation, depigmentation and regeneration, and the hair follicle response to UVR.</i></p> <p>Session Chairs: Cheng-Ming Chuong, Masatake Osawa</p> <ul style="list-style-type: none"> Critical Role of WNT Signaling in Follicular Melanocyte Stem Cells in Adult Skin [20 mins] <i>Speaker: Mayumi Ito</i> The occurrence of lentiginos and hair graying in one disorder with aberrant differentiation as the pathological mechanism [15 mins] <i>Yiqun Shellman</i> Mitf and hair graying; a direct link to innate immunity [15 mins] <i>Melissa Harris</i> Epilation induces hair and skin hyperpigmentation by upregulating endogenous EDN3 expression in mice [10 mins] <i>Ling Hou</i> Rat coat color mutations: their introduction and availability from the National Bio Resource Project for the Rat [10 mins] <i>Takashi Kuramoto</i>
-----------------	---------	--


	Tower Court C	<p>CS22. Quality of Life in Pigmentary Disorders: Melanoma, Vitiligo and Hyperpigmentation</p>
--	---------------	---

		<p><i>This session will facilitate interaction between quality of life experts in melanoma and those from other fields to stimulate development of research that will support these fields.</i></p> <p>Session Chairs: Nikolic Dejan, Robert Dellavalle</p> <ul style="list-style-type: none"> • Health related quality of life in melanoma patients [20 mins] <i>Speaker: Nikolic Dejan</i> • Burden of vitiligo, the dark side of whiteness [20 mins] <i>Speaker: Khaled Ezzedine</i> • Burden of skin pigmentary diseases [20 mins] <i>Speaker: Robert Dellavalle</i> • In silico data to support elevated perceived stress levels in vitiligo patients [15 mins] <i>Speaker: Caroline Le Poole</i> • Ashy Dermatitis, long term follow-up and quality of life data [15 mins] <i>Marcel Bekkenk</i>
	Tower Court D	<p>CS23. Melasma - Basic and Clinical Advances <i>This session will address mechanisms of induction of melasma, and approaches to treatment and prevention.</i></p> <p>Session Chairs: Jack Arbiser, Hideya Ando, Kyoung Chan Park</p> <ul style="list-style-type: none"> • Strategies for prevention or treatment of hyperpigmentary disorders [20 mins] <i>Speaker: Hideya Ando</i> • How to Understand Melasma for the Effective Treatment [20 mins] <i>Speaker: Kyoung Chan Park</i> • Role of endothelial cells in the melasma pathogenesis [20 mins] <i>Speaker: Hee Young Kang</i> • Similarities and Differences in Gene Expression between Various Facial Hyperpigmented Spots [10 mins] <i>Tomohiro Hakozaki</i> • Protein Nanocages for Cutaneous Drug Delivery [10 mins] <i>Sathya Moorthy Bhaskar</i> • Arginase-2, a miR-1299 target, enhances pigmentation in melasma by reducing melanosome degradation via senescence induced autophagy inhibition [10 mins] <i>Ai-Young Lee</i>
1:30pm - 3:15pm	Grand Ballroom II	<p>CS24. Melanoma: Diagnosis and Imaging <i>This session will address pathologic diagnosis of melanoma, molecular tools for rating melanoma diagnosis and prognosis, new imaging approaches for skin tumors, and approaches for more accurate early diagnosis of melanoma.</i></p> <p>Session Chairs: James Grichnik, Whitney High, Peter Soyer</p> <ul style="list-style-type: none"> • Advances in clinical skin imaging of melanoma and pigmentary skin disorders using multiphoton microscopy [20 mins] <i>Speaker: Mihaela Balu</i> • The Role of Clinicians, Consumers and Artificial Intelligence in the Diagnosis of Skin Lesions [20 mins] <i>Speaker: Peter Soyer</i> • Artificial Intelligence, Deep Learning, and Melanoma [20 mins] <i>Speaker: Roberto Novoa</i> • Continued evaluation of a 31-gene expression profile to predict metastasis in an expanded cohort of 782 cutaneous melanoma patients [15 mins] <i>Robert W. Cook</i> • Development and validation of a bright-field RNA in situ hybridization assay for the accurate diagnosis of atypical melanocytic nevi and melanoma [15 mins] <i>Speaker: Xiao-Jun Ma</i> • Baseline peripheral blood ratios are associated with microscopic metastases of cutaneous melanoma to the sentinel lymph node [15 mins] <i>Alyss V. Robinson</i>
3:00pm - 3:30pm	Grand Ballroom I	REFRESHMENT BREAK
3:30pm - 5:00pm	Grand Ballroom II	<p>Concurrent Sessions 25-28</p> <p>CS25. Intracellular Signaling in Melanoma</p>

		<p><i>This session will address recent advances in melanoma signaling pathways and identify new opportunities for treatment.</i></p> <ul style="list-style-type: none"> • SMAD signaling promotes melanoma metastasis independently of phenotype switching [20 mins] <i>Speaker: Lukas Sommer</i> • In vivo reporting on MEK1/2-CDK4/6 inhibitor schedules and mTOR-S6 resistance mechanisms [20 mins] <i>Speaker: Andrew Aplin</i> • BRD9 (Bromodomain Containing Protein 9) Plays Roles in Melanogenesis and Melanoma Proliferation [10 mins] <i>Tupa Basuroy</i> • Lack of MITF affects morphology, proliferation and migration of human SKMEL28 melanoma cells [10 mins] <i>Remina Dilixiati</i> • MITF, TFEB and TFE3 in melanoma – Regulation and interaction [10 mins] <i>Josue Ballesteros Alvarez</i> • Transcriptional co-activators YAP1 and TAZ have both shared and unique pathways driving melanoma [10 mins] <i>Jason Lui</i> • MAP kinase pathway inhibitor responses and resistance mechanisms in melanomas with BRAF fusions [10 mins] <i>Jacqueline A. Turner</i>
	Tower Court C	<p>CS26. Giant Congenital Nevi Basic and Translational Research <i>This session will address research through to clinical issues in managing and treating giant congenital nevi.</i></p> <p>Session Chairs: Mark Beckwith, Joseph Malvey, Veronica Kinsler</p> <ul style="list-style-type: none"> • From simple birthmarks to a neurocutaneous syndrome, lessons learned about CMN [20 mins] <i>Speaker: Harper Price</i> • Congenital nevi: from the clinical phenotype to molecular biology [25 mins] <i>Speaker: Joseph Malvey</i> • The pattern of birthmarks suggests an unknown population of melanoblasts [25 mins] <i>Speaker: Veronica Kinsler</i> • Final CMN colour is significantly associated with normal skin pigmentation, not with immediate postnatal CMN colour - Implications for early superficial removal [10 mins] <i>Satyamaanasa Polubothu</i> • Dermoscopy of small and medium congenital melanocytic nevi in infants and children [10 mins] <i>Pierre Vabres</i>
	Windows	<p>CS27. Melanoma: Heterogeneity and Microenvironment <i>This session will address effects of the microenvironment on melanoma, on tumor plasticity, and on the changes in cellular signaling that influence progression and prognosis.</i></p> <p>Session Chairs: Dorothy Bennett, Mark Shackleton, Anja Bosserhoff</p> <ul style="list-style-type: none"> • Molecular Changes in Melanoma Modifying the Tumor Microenvironment [20 mins] <i>Speaker: Anja Bosserhoff</i> • MITF regulates dynamic melanoma heterogeneity [20 mins] <i>Speaker: Nikolas Haass</i> • Regulation of melanoma heterogeneity by stem cell genes [20 mins] <i>Speaker: Mayumi Fujita</i> • S897E-EphA2 drives an amoeboid melanoma phenotype that metastasizes to the brain [10 mins] <i>Inna Smalley</i> • WISP1 Stimulates Melanoma Cell Invasion and Tumor Metastasis by Promoting Epithelial–Mesenchymal Transition (EMT) [10 mins] <i>Wentao Deng</i> • The non-cell autonomous role of Edn3/Ednrb signaling during melanoma lung metastasis formation [10 mins] <i>Juliano Freitas</i>
	Tower Court D	<p>CS28. Melanoma: Emerging Therapies II <i>This session will address ways to enhance present immune therapies,</i></p>

		<p><i>treatments using genetically modified T cells, treatments that activate various immune effectors, new vaccines for melanoma, and predictive biomarkers.</i></p> <p>Session Chair: Kim Margolin, Theresa Medina</p> <ul style="list-style-type: none"> • T cell profiling in the TME and reversing T cell anergy [25 mins] <i>Speaker: Adil Daud</i> • Neoadjuvant therapy of melanoma [25 mins] <i>Speaker: Ahmad Tarhini</i> • Radiation therapy and checkpoint inhibitors for melanoma: are we the match or the flame? [20 mins] <i>Speaker: David Raben</i> • Modified T-cell therapeutics - where do we go next? [20 mins] <i>Speaker: Kenneth Grossman</i>
5:00pm - 6:00pm	Grand Ballroom II	IFPCS General Assembly
7:00pm - 10:00pm	Denver Art Museum (North Building)	Evening Social & Awards

 info@ipcc2017.com
 Phone: + 1 604 688 9655

 Fax: + 1 604 685 3521

 [Join our Mailing List](#)

agcm0100.cfm 2017.08.26 • [PowerSite](#) 2.82 • © 2018 MCI